Managing toxic shock syndrome with antibiotics

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 8, 2004, Pages 1701-1710

  Annane, Djillali ^a   Clair, Bernard ^a   Salomon, Jérôme ^a  

^a RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

lactam; Antimicrobial resistance; Clindamycin; Cytokines; Exotoxins; Multiple organ failure; Staphylococcal toxins toxic shock syndrome toxin; Staphylococcus aureus; Streptococcus pyogenes; Superantigens; T cells; Toxic shock

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZLOCILLIN; BACTERIAL TOXIN; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFALOTIN; CEFAMANDOLE; CEFAPIRIN; CEFAZOLIN; CEFMETAZOLE; CEFONICID; CEFORANIDE; CEFOTETAN; CEFOXITIN; CEFUROXIME; CLINDAMYCIN; LINCOSAMIDE DERIVATIVE; METICILLIN; MEZLOCILLIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; CELL INTERACTION; CLINICAL FEATURE; DRUG CHOICE; DRUG MECHANISM; HUMAN; INFLAMMATION; MORTALITY; NONHUMAN; PATHOGENESIS; PREVALENCE; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME;

ANTI-BACTERIAL AGENTS; HUMANS; RISK FACTORS; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS;

EID: 4344669987     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.8.1701     Document Type: Review

References (63)

1. MARRACK P, KAPPLER J: The staphylococcal enterotoxins and their relatives. Science (1990) 248:705-711.
2. JUPIN C, ANDERSON S, DAMAS C, ALOUF JE, PARANT M: Toxic shock syndrome toxin 1 as an inducer of human tumour necrosis factors and gamma interferon. J. Exp. Med. (1988) 167:752-761.
3. OKUSAWA S, GELFAND J, IKEJIMA T et al.: Interleukin 1 induces a shock like state in rabbit. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. (1988) 81:1162-1172.
4. KOTZIN BL, LEUNG DY, KAPPLER J, MARRACK P: Superantigens and their potential role in human disease. Adv. Immunol. (1993) 54:99-166.
5. ALOUF JE, MULLER-ALOUF H: Staphylococcal and streptococcal superantigens: molecular, biological and clinical aspects. Int. J. Med. Microbiol. (2003) 292:429-440.
6. PROFT T, SRISKANDA S, YANG L, FRASER JD: Superantigens and streptococcal toxic shock syndrome. Emerg. Infect. Dis. (2003) 9:1211-1218.
7. DARENBERG J, SÖDERQUIST B, NORMAK BH, NORRBY-TEGLUND A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin. Infect. Dis. (2004) 38:836-842.
8. BECKER K, FRIEDRICH AW, LUBRITZ G, WEILERT M, PETERS G, EIFF V: Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J. Clin. Microbiol. (2003) 41:1434-1439.
9. HERWALD H, CRAMER H, MORGELIN M, RUSSEL W, SOLLENBERG U, NORRB, J: M protein, a classical bacteria] virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell (2004) 116(3):367-379.
10. TOPPEL AW, RASMUSSEN M, ROHDE M, MEDINA E, CHHATWAL GS: Contribution of protein G-related alpha2-macroglobulin-binding protein to bacterial virulence in a mouse skin model of group A streptococcal infection. J. Infect. Dis. (2003) 187:1694-1703.
11. SEIDEL SS, GERLACH D, GUNTHER E, RODEL J, STRAUBE E, SCMIDT KH: Superantigen-like gene(s) in human pathogenic Streptococcus dysgalactiae, subs equisimilis: genomic localisation of the gene encoding streptococcal pyrogenic exotoxin G (speG(dys)). FEMM. Immunol. Med. Microbiol. (2002) 34:159-167.
12. CRUM NF, WALLACE MR: Group B streptococcal necrotizing fasciitis and toxic shock-like syndrome: a case report and review of the literature. Scand. J. Infect. Dis. (2003) 35(11-12):878-881.
13. LU HZ, WENG XH, ZHU B et al.: Major outbreak of toxic shock-like syndrome caused by Streptococcus mitis. J. Clin. Microbiol. (2003) 41(7):3051-3055.
14. FACKLAM R, BEALL B, EFSTRATIOU A et al.: emm, typing and validation of provisional M types for group A streptococci. Emerg. Infect. Dis. (1999) 5:247-253.
15. HOGE CW, SCHWARTZ B, TALKINGTON DF, BREIMAN RF, MACNEIL EM, ENGLENDER SJ: The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. JAMA (1993) 269:384-389.
16. HO PL, JOHNSON DR, YUE AW: Epidemiologic analysis of invasive and non-invasive group and streptococcal isolates in Hong Kong. J. Clin. Microbiol. (2003) 41:937-942.
17. MIYOSHI-AKIYAMA T, ZHAO J, KIKUCHI K, KATO H, SUZUKI R, ENDOH M: Quantitative and qualitative comparison of virulence traits, including murine lethality, among different M types of group A streptococci. J. Infect. Dis. (2003) 187:1876-1887.
18. ERIKSSON BK, NORGREN M, MCGREGOR K, SPRATT BG, NORMARK BH. Group A streptococcal infections in Sweden: a comparative study of invasive and noninvasive infections and analysis of dominant T28 emm28 isolates. Clin. Infect. Dis. (2003) 37:1189-1193.
19. O'BRIEN KL, BEALL B, BARRETT N et al.: Epidemiology of invasive group A Streptococcus disease in the United States 1995-1999. Clin. Infect. Dis. (2002) 35:268-276.
20. EFSTRATIOU A: Group A streptococci in the 1990s. J. Antimicrob. Chemother. (2000) 45:3-12.
21. TERAO Y, KAWABATA S, NAKATA M, NAKAGAWA I, HAMADA S: Molecular characterization of a novel fibronectin-binding protein of Streptococcus pyogenes strains isolated from toxic shock-like syndrome patients. J. Biol. Chem. (2002) 277:47428-35.
22. STEVENS DL: Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg. Infect. Dis. (1995) 1:69-78.
23. KOTB M, NORRBY-TEGLUND A, MCGEER A et al.: An immunogenetic and molecular basis for differences in outcomes of invasive groups A streptococcal infections. Nat. Med. (2002) 8:1398-1404.
24. AKESSON P, RASMUSSEN M, MASCINI E et al.: Low antibodies levels against cell wall-attached proteins of Streptococus pyogenes predispose for severe invasive disease. J. Infect. Dis. (2004) 189:797-804.
25. ERIKKSON BK, ANDERSSON J, HOLM SE, NORGREN M: Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin. Infect. Dis. (1998) 27:1428-1436.
26. BAXTER F, MCCHESNEY J: Severe group A streptococcal infection and streptococcal toxic shock syndrome. Can. J. Anaesth. (2002) 47:1129-1140.
27. BEN-ABRAHAM R, KELLER N, VERED R, HAREL R, BARZILAY Z, PARET G: Invasive group A streptococcal infections in a large tertiary medical center. Infection (2002) 30:81-85.
28. TODD J, FISHAUT M, KAPRAL F, WELCH T: Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet (1978) 2:1116-1118.
29. SHANDS KN, SCHMID GP, DAN BB et al.: Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N. Engl. J. Med. (1980) 303:1436-1442.
30. MILLS JT, PARSONNET J, TSAI YC, KENDRICK M, HICKMAN RK, KASS EH: Control of production of toxic-shock-syndrome toxin-1 (TSST-1) by magnesium ion. J. Infect. Dis. (1985) 151:1158-1161.
31. MUSSER JM, SCHLIEVERT PM, CHOW AW et al.: A single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndrome. Proc. Natl. Acad. Sci. USA (1990) 87:225-229.
32. HAJJEH RA, REINGOLD A, WEIL A, SHUTT K, SCHUCHAT A, PERKINS BA: Toxic shock syndrome in the United States: surveillance update, 1979-1996. Emerg. Infect. Dis. (1999) 5:807-810.
33. LINA G, VANDENESCH, ETIENNE J: Staphylococcal and streptococcal pediatric toxic syndrome from 1998 to 2000. Arch. Pediatr. (2001) 8:769s-775s.
34. LANG C, BEHNKE H, BITTERSOHL J et al.: Special features of intensive care of toxic shock syndrome. Review and case report of a TSST-1 associated toxic-shock syndrome with adult respiratory distress syndrome and multi organ failure from a staphylococcal panaritium. Anaesthesist (2003) 52:805-813.
35. THE WORKING GROUP ON SEVERE STREPTOCOCCAL INFECTIONS: Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA (1993) 269:390-391.
36. REINGOLD AL, HARGRETT NT, SHANDS KN et al.: Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann. Intern. Med. (1982) 96:875-880.
37. MATSUDA Y, KATO H, YAMADA R et al.: Early and definitive diagnosis of toxic shock syndrome by detection of marked expansion of T-cell-receptor VBeta2-positive T cells. Emerg. Infect. Dis. (2003) 9:387-389.
38. ANNANE D, BELLISSANT E, CAVAILLON JM: Septic shock. Lancet (2004) (In Press).
39. VAN LANGEVELDE P, VAN DISSEL JT, MEURS CJC, RENZ J, GROENEVELD PHP: Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin 1 production by Staphylococcus aureus in both logarithmic and stationary phases of growth. Antimicrob. Agents. Chemother. (1997) 41:1682-1685.
40. GARNACHO-MONTERO J, GARCIA-GARMENDIA JL, BARRERO-ALMODOVAR A et al.: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care. Med. (2003) 31:2742-2751.
41. MACARTHUR RD, MILLER M, ALBERTSON T et al.: Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin. Infect. Dis. (2004) 38:284-288.
42. STEVENS DL, GIBBONS AE, BERGSTROM R, WINN V: The Eagle effect revisited: efficacy of clindamycin, erythromicin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. (1988) 158:23-28.
43. STEVENS DL, YAN S, BRYANT AE: Penicillin-binding-protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J. Infect. Dis. (1993) 167:1401-1405.
44. SCHLIEVERT PM, KELLY JA: Clindamycin-induced suppression of toxic shock syndrome associated exotoxin production. J. Infect. Dis. (1984) 149:471.
45. GEMMELL CG, PETERSON PK, SCHMELING D et al.: Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J. Clin. Invest. (1981) 67:1249-1256.
46. STEVENS DL, BRYANT AE, HACKETT SP: Antibiotic effect on bacterial viability, toxin production and host response. Clin. Infect. Dis. (1995) 20:S154-S157.
47. BETRIU C, SANCHEZ A, GOMEZ M, CRUCEYRA A, PICAZZO JJ: Antibiotic susceptibility of group A streptococci: a 6-year follow-up study. Antimicrob. Agents Chemother. (1993) 37:1717-1719.
48. COMAGLIA G, LIGOZZI M, MAZZARIOL A, VALENTINI M, OREFICI G, FONTANA R: Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995: the Italian Surveillance Group for Antimicrobial Resistance. Emerg. Infect. Dis. (1996) 2:339-342.
49. SEPPALA H, SKURNIK M, SOINI H, ROBERTS MC, HUOVINEN P: A novel erythromycin resistance methylase gene(emrTR) in Streptococcus pyogenes. Antimicrob. Agents. Chemother. (1998) 42:257-262.
50. CLANCY J, PETITPAS J, DIB-HAJJ H et al.: molecular cloning and functional analysis of a novel macrolides resistance to Streptococcus pyogenes. Mol. Microbiol. (1996) 22:867-879.
51. ANNANE D, BELLISSANT E, BOLLAERT P, BRIEGEL J, KEH D, KUPFER Y: Corticosteroids for treating severe sepsis and septic shock. Cochrane Database. Syst. Rev. (2004) 1:CD002243.
52. ANNANE D, SEBILLE V, CHARPENTIER C et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA (2002) 288:862-871.
53. BERNARD GR, VINCENT JL, LATERRE PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. (2001) 344:699-709.
54. DARENBERG J, IHENDYANE N, SJÖLIN J. et al.: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. (2003) 37:333-340.
55. KAWAGUCHI T, IGAKI N, KINOSHITA S et al.: A new therapeutic strategy for streptococcal toxic shock syndrome: a key target for cytokines. Intern. Med. (2003) 42:211-218.
56. DALE JB: Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine (1999) 17:193-200.
57. HU DL, OMOE K, SASAKI S et al.: Vaccination with non-toxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J. Infect. Dis. (2003) 188:743-752.
58. COLLINS LV, ERIKSSON K, ULRICH RG, TARKOWSKI A: Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock. Infect. Immun. (2002) 70:2282-2287.
59. PATEL R, ROUSE PR, FLOREZ MV et al.: Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. J. Infect. Dis. (2000) 181:230-234.
60. YORK MK, GIBBS L, PERDREAU-REMINGTON F, BROOKS GF: Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J. Clin. Microbiol. (1999) 37:1727-1731.
61. PEREZ-TRALLERO E, GARCIA C, ORDEN B, MARIMON JM, MONTES M: Dissemination of emm28 erythromycin-, clindamycin-, and bacitracin-resistant Streptococcus pyogenes in Spain. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:123-126.
62. LOWY FD: Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. (2003) 111:1265-1273.
63. ENDO H, HIGURASHI Y, OKUZUMI K, HITOMI S, KIMURA S: Changes in drug susceptibility and toxin genes in Staphylococcus aureus isolated from blood cultures at a university hospital. J. Infect. Chemother. (2003) 10:8-10.